genprowebdirectory
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2023
Boehringer Ingelheim
Drug Discovery
After Mod 2.0, What Can Be Done to Boost Adoption of Alternatives to Animal Models?
Uduak Thomas
-
September 21, 2023
0
A-Lists
Top 10 Contract Development and Manufacturing Organizations
Alex Philippidis
-
September 15, 2023
0
Bioprocessing
Connected Downstream Models for Accurate Process Predictions
John Sterling
-
June 7, 2023
0
Drug Discovery
PhoreMost Achieves Target Discovery Milestone with Boehringer Ingelheim
Jonathan D Grinstein, PhD
-
January 6, 2023
0
Drug Discovery
Boehringer Ingelheim, Enleofen Ink $1B-Per-Product Anti-IL-11 Partnership Focused on NASH, Lung Disorders
Alex Philippidis
-
January 9, 2020
0
Cancer
Boehringer Ingelheim, Lupin Launch $700M+ Cancer Therapy Collaboration Targeting KRAS
Alex Philippidis
-
September 4, 2019
0
Industry News
Boehringer Ingelheim Launches Up-to-€1.1B IPF Collaboration with Bridge Biotherapeutics
Alex Philippidis
-
July 19, 2019
0
Cancer
Expanding Cancer Immunotherapy Focus, Boehringer Ingelheim Acquires AMAL Therapeutics for Up-to-€325M
Alex Philippidis
-
July 17, 2019
0
Industry News
Boehringer Ingelheim, Yuhan Launch Up-to-$870M+ NASH Collaboration
Alex Philippidis
-
July 2, 2019
0
Cancer
PROTACs Developed with U. of Dundee Boost Boehringer Ingelheim’s Cancer Pipeline
Alex Philippidis
-
June 24, 2019
0
1
2
3
...
12
Page 1 of 12
Scroll Up
Scroll Up
